Edition:
United States

Galena Biopharma Inc (GALE.OQ)

GALE.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
26 May 2017
Change (% chg)

$-0.02 (-3.01%)
Prev Close
$0.58
Open
$0.57
Day's High
$0.58
Day's Low
$0.55
Volume
56,893
Avg. Vol
296,396
52-wk High
$49.80
52-wk Low
$0.52

GALE.OQ

Chart for GALE.OQ

About

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S),... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $21.54
Shares Outstanding(Mil.): 37.44
Dividend: --
Yield (%): --

Financials

  GALE.OQ Industry Sector
P/E (TTM): 2.62 14.31 17.43
EPS (TTM): 0.22 -- --
ROI: -0.97 -7.26 -5.41
ROE: -1.42 -6.76 -4.69

Alabama 'pill mill' doctor tied to Insys gets 21 years in prison

An Alabama doctor was sentenced on Friday to 21 years in prison for running two clinics with a colleague that prosecutors called a massive "pill mill," in a case tied to the U.S. probe of Insys Therapeutics Inc.

May 26 2017

Alabama 'pill mill' doctor tied to Insys gets 21 years in prison

An Alabama doctor was sentenced on Friday to 21 years in prison for running two clinics with a colleague that prosecutors called a massive "pill mill," in a case tied to the U.S. probe of Insys Therapeutics Inc.

May 26 2017

Alabama 'pill mill' doctor tied to Insys gets 21 years in prison

May 26 An Alabama doctor was sentenced on Friday to 21 years in prison for running two clinics with a colleague that prosecutors called a massive "pill mill," in a case tied to the U.S. probe of Insys Therapeutics Inc.

May 26 2017

Alabama doctor tied to Insys gets 20 years for illegal prescriptions

An Alabama doctor was sentenced on Thursday to 20 years in prison after being convicted with a colleague of prescribing painkillers through two clinics for no legitimate purpose, in a case tied to the U.S. probe of Insys Therapeutics Inc.

May 25 2017

BRIEF-RXI Pharma, PCI Biotech extend preclinical research collaboration

* RXI Pharmaceuticals -co and PCI Biotech announced that they are extending their preclinical research collaboration initiated April 7, 2015 Source text for Eikon: Further company coverage:

May 22 2017

Galena Biopharma reaches $7.5 million accord in U.S. opioid probe

Galena Biopharma Inc has disclosed that it has tentatively agreed to pay $7.5 million to resolve a U.S. Justice Department investigation into its marketing and promotional practices for an opioid-based pain medication.

May 11 2017

BRIEF-Rxi Pharmaceuticals posts Q1 loss per share $0.27

* Rxi Pharmaceuticals reports first quarter 2017 financial results and recent corporate highlights

May 11 2017

BRIEF-Galena Biopharma Q1 loss per share $0.45

* Galena Biopharma reports first quarter 2017 financial results

May 10 2017

BRIEF-RXI Pharmaceuticals Corp says to present an update on its consumer product development programs

* RXI Pharmaceuticals Corp says to present an update on its consumer product development programs

Apr 20 2017

BRIEF-Galena Biopharma and JGB Newton Ltd entered into waiver that amended securities purchase agreement dated May 10 - SEC Filing

* Galena Biopharma - On April 1, co and JGB Newton Ltd., entered into waiver that amended securities purchase agreement dated May 10, 2016 - SEC Filing

Apr 03 2017

More From Around the Web

Competitors

Earnings vs. Estimates